The clinical features and outcomes of COVID-19 in patients with cancer

Abstract

Author(s): Renuka Jyothi R*, K G Patel and Trapty Agarwal

Objective: A clinical features and outcome of cancer patients through new Corona Virus Disease (COVID-19) were the focus of this retrospective investigation.

Materials and methods: 52 cancer patients with COVID-19 had medicinal report, laboratory data, and radiologic findings that were gathered, summarized, and used to determine clinical features and outcomes. There were 50 cancer individuals overall with COVID-19. The 52 COVID-19's median age-positive cancer patient was 65 years old (34 years–98 years). There were 33 (3%) mild patients and 19 (5%) severe patients.

Results: The most common cancer kind (11%) was lung cancer. Fever (14%) was among the most prevalent symptoms, followed by a dry cough (10%), chest discomfort (7%), and fatigue (6%). The most prevalent symptom in 33 (63.5%) patients with comorbidities was hypertension (18%). At the time of admission, 26 patients (70.8%) had pneumonia. Patients with mild and severe conditions had a reduction in lymphocytes (0.6109/L). C-reactive protein, procalcitonin, D-dimer, and lactate dehydrogenase had median values of 318 U/L, 2.8 mg/L, 70.5 mg/L, and 0.3 ng/mL, in that order. These values substantially improved in severe patients compared to moderate patients. Interleukin-6 levels varied significantly (13.6 pg/mL), rising in mutually moderate and severe individuals.

Conclusion: The problems that were seen in 29 (50.8%) of the patients. 11 cancer sufferers (20.2%) lost their lives. Infection rates for the severe discriminating respiratory pattern coronavirus 2 were greater in cancer patients than in the universal populations, and patients with COVID-19 had worsening symptoms and less favourable outcome.

Share this article